Researchers Identify Why Hospitals May Not “Get in the Ring” to Fight “Superbug”
PHILADELPHIA – (Oct. 8, 2014) – Numerous experts and policy makers have called for hospitals to screen patients for methicillin-resistant Staphylococcus aureus (MRSA) infections and isolate anyone testing positive to prevent the spread of these so-called “Superbugs” in healthcare settings. Several states have enacted laws requiring patients be screened for MRSA upon admission.
LA BioMed Researchers Surveyed Emergency Patients Tested for THC Levels
LOS ANGELES – (Oct. 1, 2014) – Surveying patients with traumatic brain injury, a group of Los Angeles Biomedical Research Institute (LA BioMed) researchers reported today that they found those who tested positive for THC, the active ingredient in marijuana, were more likely to survive than those who tested negative for the illicit substance.
Investigator(s):
The Lundquist Institute
Researchers Find Method for Replacing Missing Enzyme in the Brain.
LOS ANGELES – (Oct. 1, 2014) – MPS IIIB is a devastating and currently untreatable disease that causes progressive damage to the brain, leading to profound intellectual disability, dementia and death — often before reaching adulthood.
Patients benefit from minimally invasive procedures.
LOS ANGELES – (September 23, 2014) –
Laparoscopic cholecystectomy, a minimally invasive procedure to remove the gallbladder, is one of the most common abdominal surgeries in the U.S. Yet medical centers around the country vary in their approaches to the procedure with some moving patients quickly into surgery while others wait.
New Research Executive Brings Wealth of Experience to Institute
LOS ANGELES – (August 18, 2014) – Bringing a wealth of experience in research administration, Susan D. Rubin recently joined Los Angeles Biomedical Research Institute (LA BioMed) in a newly created role of chief operating officer and general counsel.
LOS ANGELES – (August 15, 2014) – Los Angeles Biomedical Research Institute (LA BioMed) recently named six new members to its Board of Directors, expanding the board’s expertise in the law, scientific research, engineering, development, public affairs and more.
David B. Duthu, Dr. David Heber, Joan Hood Jones, Anne-Merelie Murrell, Barnet Resnick and Dan Rosenfeld have joined the board of LA BioMed, one of the nation’s leading nonprofit independent research institutes.
Investigator(s):
Kamyar Kalantar-Zadeh, MD, PhD
Kamyar Kalantar-Zadeh, the world’s foremost expert on end-stage kidney disease, has followed his research to the controversial proposition that obesity might be a patient’s best friend in the hour of greatest need.
Recent findings by Kalantar-Zadeh and some of his colleagues have landed him square in the middle of an “obesity paradox,” which is the subject of sometimes heated debate among physicians, researchers and public health officials.
Article from Wakingtimes.com
A look at the psychoactive brew that brings users a spiritual payoff for their “work”
In a greenhouse at the University of Minnesota, Dennis McKenna walks past the cacao (chocolate) and the Punica (pomegranate), and strides straight to the back corner, where the vines of the plant Banisteriopsis have twisted around each other — and nearby electrical cords — to reach the room’s rafters.
“There’s also a problem that the ‘normal’ ranges for one
laboratory may be decidedly different than they are for another
laboratory,” says Ronald Swerdloff, chief endocrinologist at Harbor
UCLA Medical Center in California and LA Biomed Inv.
Testosterone supplements promise men a butch boost of resurrected
libido, energy and mood. But there’s a better way to restore
virility
“REDUCED sex drive? Decreased energy? Unwanted mood or body changes?
Is it low testosterone?”
Kythera Biopharmaceuticals’ new drug application (NDA) for its ATX-101, a submental contouring injectable drug, has been accepted for filing by the US Food and Drug Administration (FDA).
According to Kythera Biopharmaceuticals, the ATX-101 NDA will be subject to a standard review and will have a prescription drug user fee act (PDUFA) action date of 13 May 2015. The company submitted the NDA in May 2014.
The FDA’s Division of Dermatology and Dental Products is also planning to hold an Advisory Committee meeting on the company’s ATX-101 application during the review.